Print
Email
Print Edition Stories
MHT's Marc Songini: Technology to keep seniors healthy
MHT's Marc Songini: Researchers focus on macular degeneration
MHT's Marc Songini: RI plans launch of cord blood center
Idera Pharmaceuticals Inc. has initiated a phase 1 clinical trial using the company’s Hepatitis C drug target, known as IMO-2125 in combination with another treatment called ribavirin.
The Cambridge-based biotechnology company’s trial is geared towards patients who are treatment-naive, meaning they have never received treatment for Hepatitis C (HCV). The company also has an ongoing trial using the drug target alone, as a monotherapy.
The drug candidate will be administered as an injection once a week for four weeks in combination with daily oral administration of standard doses of ribavirin. The trial will treat groups of 15 patients, with receiving IMO-2125 plus ribavirin treatment and the other three receiving only ribavirin. The clinical trial is expected to be conducted at five or more sites in France and Russia.
Idera develops drug candidates to treat infectious and autoimmune diseases, cancer and respiratory diseases, in addition to its use as vaccine adjuvants. Its candidates are designed to modulate specific Toll-like receptors, a family of immune system receptors which direct immune system responses.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
